ArticleJournal of medical case reports2025
Targeting MET and KRAS G12C co-occurring mutation in metastatic adenoid cystic carcinoma of the trachea: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMET and KRAS comutation in the same group of cells of primary tracheal adenoid cystic carcinoma is extremely rare; there is no standard of care for patient with metastatic disease. CASE PRESENTATION: We report a 42-year-old treatment-naïve Chinese male patient with metastatic tracheal adenoid cystic carcinoma harboring a MET p.D1010Y and KRAS p.G12C comutation. The patient responded well to the MET inhibitor crizotinib and MEK inhibitor trametinib combination therapy, but had progression when he discontinued trametinib because of grade III rashes on the face and trunk. With the reintroduction of trametinib with a dose reduction, his metastatic lesions shrank after 2 months of therapy.
conclusionMET p.D1010Y and KRAS p.G12C comutation is extremely rare and could happen concurrently in the same group of cells of metastatic tracheal adenoid cystic carcinoma; crizotinib combined with trametinib is effective, and the toxicities are manageable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.